HEPHAISTOS-Pharma

We are thrilled to announce the nomination of Christel Lonneux as our new CFO (Chief Financial Officer) at HEPHAISTOS-Pharma 👏 Christel has a great experience in financial auditing, Finance and HR management in other Biotech companies 💊 She will be based in #liege, #Belgium and will be in charge of the financial management of the company both in France 🇫🇷 and in Belgium 🇧🇪 Welcome to the #HEPHAISTOSTeam Martine Caroff Alexey Novikov Jerome Kerzerho Capucine Phelip Anaïs DEBESSET Simon Pico Christophe Ansiaux

Thanks to the BioLabs France and Sanofi team for inviting us at #HotelDieu to give a talk on #PediatricCancer and share a discussion moment together 🥂 👉Jerome Kerzerho and Simon Pico were able to present HEPHAISTOS-Pharma data against #Sarcoma including metastatic Osteosarcoma where we could bring a therapeutic solution for patients 🦴 Thanks to the other presenters : 👉Iris Valtingojer, Childhood Cancer Research Lead at Sanofi 👉André Baruchel, Onco-pediatric Department, Hôpital Robert Debré, AP-HP, Assistance Publique - Hôpitaux de Paris, 👉Emily Fang et Kyle Giesler InFocus Therapeutics Sasha Lièvre Christophe Tallec Martine Caroff Capucine Phelip Anaïs DEBESSET Christophe Ansiaux Christel Lonneux

Tomorrow Thursday 9:30-10:30 CET, I will have the pleasure to participate to a roundtable organized by Bpifrance during the #BIG event #EUROQUITY On the following subject : Early-stage #DeepTech, focus on the BioTech with HEPHAISTOS-Pharma With the following participants : 👉 Eric Chetaille one of our #BusinessAngel at Angels Santé and Scientific Advisory Board member in charge of clinical strategy 👨⚕️ 👉Alain Pujol Co president at France Angels who will moderate the talk 🎙 We will discuss about the way we managed to raise money with Business Angels and #NonDilutive #Fundings like #grants and how we work together today and prepare our next milestones and fundraising to finance clinical phases. Here is the link to participate : https://lnkd.in/euNu94QS Martine Caroff Alexey Novikov Jerome Kerzerho Simon Pico Capucine Phelip Anaïs DEBESSET Christophe Ansiaux Christel Lonneux

Thanks to Jerome Kerzerho and Simon Pico for presenting our data and clinical perspectives against Childhood Cancer 🔬

Happy to welcome 🤗 Christophe Ansiaux in the HEPHAISTOS-Pharma team as Manufacturing transfer manager 🔬🔜🏭 Christophe is our first employee in #Liege #Belgium 🇧🇪 and we will be based at the #GIGA institute in the CHU de Liège 🏥 He will recruit and manage a team of researchers preparing analytical Quality Controls and process development for our GMP transfer that started with CDMO 🏭 If you have experience in QC and formulation development and you want to join the team, send your CV and you motivation e-mail to 👉 recrutement@hephaistos-pharma.com Our objectives is to have a GMP batch ready next year to engage regulatory tox and move forward to clinical phase 1 💉 Noshaq Eric Brandt Frédéric Schynts Martine Caroff Jerome Kerzerho Simon Pico Capucine Phelip Alexey Novikov Anaïs DEBESSET Christel Lonneux

Thanks to the WACKER team for welcoming us today in Amsterdam 🇳🇱 It was a great occasion to visit a #GMP manufacturing site and to have a technical discussion on Downstream Process #DSP development and Formulation #Scaleup 💉 HEPHAISTOS-Pharma is preparing industrialization of its manufacturing process with the aim of conducting regulatory tox studies and clinical trials in #oncology. Thanks to Ronald Eulenberger Sandra Verhaagh Jos Vergeest Eric Verhagen Michael van der Horst Dr. Santosh Vijayan Eger Boonstra Joris van der Schoor Moira Monika Schuler Rob V. Martine Caroff Alexey Novikov Simon Pico Jerome Kerzerho Capucine Phelip Anaïs DEBESSET

#TalentsCNRS, #innovation, #industriesSanté, #biotech, #deeptech, #immunologie, #cancer   Échos de Viva Technology (3) !   A l’interface de l’immunologie et de l’oncologie, la société de biotechnologie HEPHAISTOS-Pharma, présente sur le stand du CNRS - Centre national de la recherche scientifique au salon Viva Technology, est emblématique d’un partenariat particulièrement réussi entre sphère académique et monde de l’entreprise.   Créée en 2018 et dirigée par Frédéric CAROFF, la startup développe une nouvelle génération d’immunothérapies contre le cancer. L’effet de stimulation du système immunitaire lié aux endotoxines a été démontré dans divers modèles animaux et sur plusieurs modèles de tumeurs : lymphomes et ostéosarcomes. Parmi les prochaines étapes figurent l'industrialisation de la production et les études réglementaires de toxicité en vue du dépôt d’une demande d'autorisation pour réaliser un essai clinique en Europe.   Jean-Luc Moullet, Carole Chrétien, Pauline Normand, CNRS Innovation, HEPHAISTOS-Pharma, PULSALYS, Martine Caroff, Frédéric CAROFF, Simon Pico, Charles Dumontet

🚀 We are very happy to announce today that HEPHAISTOS-Pharma secured 10,3 M€ to reach clinical stage. This was officially announced during the #Meet2Win #Oncology event organized by MATWIN We want to thank our private investors #VentureCapital who support us. We are delighted to have you on board : 👉 Florian Denis from Elaia 👉 Ingrid Kelly Spillmann from xista science ventures 👉 Jerome Majoie from fondation fournier majoie pour l'innovation 👉 Frédéric Schynts from Noshaq As welll as the #BusinessAngels from Angels Santé and FBA - Femmes Business Angels Eric Chetaille who joined the SAB Thanks to our institutional financing : 👉 Bpifrance #iNov 👉 European Innovation Council and SMEs Executive Agency (EISMEA) 👉 ANR (Agence nationale de la recherche) #France2030 Thanks also to the Matwin team & coaches Lucia ROBERT Jean-Yves Bonnefoy Emmanuel Conseiller, PhD, HDR Boutaina Daher who are doing a great work at connecting investors / Biotech / Pharmas This great news could not be possible without the great work from the HEPHAISTOS-Pharma team Martine Caroff Alexey Novikov Jerome Kerzerho Simon Pico Capucine Phelip 👏 👏 👏 and our great academic partners Charles Dumontet Jean-Yves Blay Aurélie Dutour 🔬 Let's go to the clinic, patients are waiting for a cure. We are now members of the Paris Saclay Cancer Cluster (PSCC) who helps us for the next financing rounds #SeriesA. They put us in contact with great scientific expert from Gustave Roussy like Aurélien Marabelle and international experts in the network of Eric Vivier. We strongly believe in the capacity of #PSCC to gather forces against cancer in the next few years.

HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round 🇫🇷 🔬 Elaia leads a consortium previously initiated by xista science ventures, the fondation fournier majoie pour l'innovation and Noshaq. “ELAIA has a proven track record in supporting biotech companies through to the clinic and success, and we are delighted to have them on board,” said Frédéric CAROFF, CEO and co-founder of HEPHAISTOS-Pharma. 

I will be attending to #Meet2Win Bordeaux Convention on 16-17 May 2024. I will be pleased to meet other pharma companies for building collaborations and Series A investors interested in oncology #therapeutic. 🫁🧠 Thanks to the MATWIN team for organizing this event Lucia ROBERT Stéphanie Dhont Boutaina Daher Fabrice Barlesi Jean-Yves Bonnefoy 🤝 Thanks to the investors participating to the #MATWIN Board 👉Jerome Majoie from fondation fournier majoie pour l'innovation 👉Florian Denis from Elaia They are bringing their great experience in #oncology. We will present a poster summarizing the great data obtained by the HEPHAISTOS-Pharma team Jerome Kerzerho Capucine Phelip Alexey Novikov Simon Pico Martine Caroff